<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="retraction" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1639679</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2025.1639679</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Retraction</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Retraction: Eupalinolide J suppresses the growth of triple-negative breast cancer cells via targeting STAT3 signaling pathway</article-title>
<alt-title alt-title-type="left-running-head">Frontiers Editorial Office</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2025.1639679">10.3389/fphar.2025.1639679</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<collab>Frontiers Editorial Office</collab>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/228891/overview"/>
</contrib>
</contrib-group>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Approved by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/20178/overview">Frontiers Editorial Office</ext-link>, Frontiers Media SA, Switzerland</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Frontiers Editorial Office, <email>research.integrity@frontiersin.org</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>11</day>
<month>06</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1639679</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>06</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>03</day>
<month>06</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Frontiers Editorial Office.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Frontiers Editorial Office</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="retracted-article" journal-id="Front. Pharmacol." journal-id-type="nlm-ta" xlink:href="10.3389/fphar.2019.01071" ext-link-type="doi">A Retraction of the Original Research Article <article-title>Eupalinolide J suppresses the growth of triple-negative breast cancer cells via targeting STAT3 signaling pathway</article-title> by Lou C, Chen Y, Zhang J, Yang B and Zhao H (2019). Front. Pharmacol. 10:1071. doi: <object-id>10.3389/fphar.2019.01071</object-id>
</related-article>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Pharmacology of Anti-Cancer Drugs</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>The journal retracts the 19 September 2019 article cited above.</p>
<p>Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers&#x2019; policies.</p>
<p>This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors received a communication regarding the retraction and had a chance to respond. This communication has been recorded by the publisher.</p>
<p>Frontiers would like to thank the users on PubPeer for bringing the published article to our attention.</p>
</body>
</article>